Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data
نویسندگان
چکیده
منابع مشابه
Factor VIII products and inhibitors in severe hemophilia A.
n engl j med 368;15 nejm.org april 11, 2013 1456 improves outcomes as compared with less complete revascularization.2 However, our trial involved highly experienced interventional cardiologists and surgeons who attempted to maximize the completeness of revascularization. Substantially more complete PCI-based revascularization is therefore unlikely in other institutions. Serruys and Farooq sugge...
متن کاملAthletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis.
OBJECTIVES We sought to determine joint outcomes relative to impact level of athletic participation among school-aged children who had hemophilia and were taking prophylactic factor replacement, as well as to investigate prognostic factors for joint outcomes. METHODS School-aged boys with severe hemophilia A or B at a single center were included in the study. Clinical data on baseline joint s...
متن کاملDetection of Factor VIII Inhibitors in Hemophilia A Patients
Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...
متن کاملRecombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
BACKGROUND Prophylactic factor replacement, which prevents hemarthroses and thereby reduces the musculoskeletal disease burden in children with hemophilia A, requires frequent intravenous infusions (three to four times weekly). OBJECTIVE Kids A-LONG was a phase 3 open-label study evaluating the safety, efficacy and pharmacokinetics of a longer-acting factor, recombinant factor VIII Fc fusion ...
متن کاملPegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
Current management of hemophilia A includes prophylaxis with factor VIII (FVIII) replacement every 2 to 3 days. BAX 855, Baxalta's pegylated full-length recombinant FVIII (rFVIII), was designed to increase half-life and, thus, reduce the frequency of prophylactic infusions while maintaining hemostatic efficacy. BAX 855 was evaluated in previously treated patients with severe hemophilia A who we...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Rheumatology
سال: 2015
ISSN: 0315-162X,1499-2752
DOI: 10.3899/jrheum.141236